In vivo specificity and efficacy of the agents were evaluated by MRI in a subcutaneous wound healing model and experimental glioma with Mrc1+/+ without and with D-mannose treatment, Mrc1+/-, and Mrc1-/- mice, and in stroke. Here, MRC1 is linked to central nervous system cancer.